A phase I trial investigating Iomab-B [anti-CD45-monoclonal-antibody-BC8-I-131] in patients with relapsed and refractory Hodgkin Lymphoma

Trial Profile

A phase I trial investigating Iomab-B [anti-CD45-monoclonal-antibody-BC8-I-131] in patients with relapsed and refractory Hodgkin Lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Mar 2016

At a glance

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top